Transcription factor EB reprograms branched-chain amino acid metabolism and promotes pancreatic cancer progression via transcriptional regulation of BCAT1

Abstract

Pancreatic cancer cells have a much higher metabolic demand than that of normal cells. However, the abundant interstitium and lack of blood supply determine the lack of nutrients in the tumour microenvironment. Although pancreatic cancer has been reported to supply extra metabolic demand for proliferation through autophagy and other means, the specific regulatory mechanisms have not yet been elucidated. In this study, we focused on transcription factor EB (TFEB), a key factor in the regulation of autophagy, to explore its effect on the phenotype and role in the unique amino acid utilisation pattern of pancreatic cancer cells (PCCs). The results showed that TFEB, which is generally highly expressed in pancreatic cancer, promoted the proliferation and metastasis of PCCs. TFEB knockdown inhibited the proliferation and metastasis of PCCs by blocking the catabolism of branched-chain amino acids (BCAAs). Concerning the mechanism, we found that TFEB regulates the catabolism of BCAAs by regulating BCAT1, a key enzyme in BCAA metabolism. BCAA deprivation alone did not effectively inhibit PCC proliferation. However, BCAA deprivation combined with eltrombopag, a drug targeting TFEB, can play a two-pronged role in exogenous supply deprivation and endogenous utilisation blockade to inhibit the proliferation of pancreatic cancer to the greatest extent, providing a new therapeutic direction, such as targeted metabolic reprogramming of pancreatic cancer.

References

[1] OrthM, Metzger P, GerumS, et al. Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches. Radiat Oncol. 2019;14(1):141.

[2] NeoptolemosJP, KleeffJ, MichlP, Costello E, GreenhalfW, PalmerDH. Therapeutic developments in pancreatic cancer: current and future perspectives. Nat Rev Gastroenterol Hepatol. 2018;15(6):333-348.

[3] Vander HeidenMG, Cantley LC, ThompsonCB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science (New York, NY). 2009;324(5930):1029-1033.

[4] Encarnación-RosadoJ, SohnASW, Biancur DE, et al. Targeting pancreatic cancer metabolic dependencies through glutamine antagonism. Nature. Cancer. 2023;5:85-99.

[5] KimSS, XuS, CuiJ, et al. Histone deacetylase inhibition is synthetically lethal with arginine deprivation in pancreatic cancers with low argininosuccinate synthetase 1 expression. Theranostics. 2020;10(2):829-840.

[6] HigashiT, SagaT, NakamotoY, et al. Diagnosis of pancreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET)—usefulness and limitations in “clinical reality”—. Ann Nucl Med. 2003;17(4):261-279.

[7] ChuGC, Kimmelman AC, HezelAF, DePinhoRA. Stromal biology of pancreatic cancer. J Cell Biochem. 2007;101(4):887-907.

[8] LiJ-T, YinM, WangD, et al. BCAT2-mediated BCAA catabolism is critical for development of pancreatic ductal adenocarcinoma. Nat Cell Biol. 2020;22(2):167-174.

[9] KamphorstJJ, NofalM, CommissoC, et al. Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein. Cancer Res. 2015;75(3):544-553.

[10] NieC, HeT, ZhangW, Zhang G, MaX. Branched chain amino acids: beyond nutrition metabolism. Int J Mol Sci. 2018;19(4):954.

[11] DeBerardinisRJ, Chandel NS. Fundamentals of cancer metabolism. Sci Adv. 2016;2(5):e1600200.

[12] LeeJH, ChoY-R, KimJH, et al. Branched-chain amino acids sustain pancreatic cancer growth by regulating lipid metabolism. Exp Mol Med. 2019;51(11):1-11.

[13] PalmieriM, ImpeyS, KangH, et al. Characterization of the CLEAR network reveals an integrated control of cellular clearance pathways. Hum Mol Genet. 2011;20(19):3852-3866.

[14] SardielloM, Palmieri M, di RonzaA, et al. A gene network regulating lysosomal biogenesis and function. Science. 2009;325(5939):473-477.

[15] KleinK, WernerK, TeskeC, et al. Role of TFEB-driven autophagy regulation in pancreatic cancer treatment. Int J Oncol. 2016;49(1):164-172.

[16] FangL-M, LiB, GuanJ-J, et al. Transcription factor EB is involved in autophagy-mediated chemoresistance to doxorubicin in human cancer cells. Acta Pharmacol Sin. 2017;38(9):1305-1316.

[17] KimJH, LeeJ, ChoYR, et al. TFEB supports pancreatic cancer growth through the transcriptional regulation of glutaminase. Cancers (Basel). 2021;13(3):483.

[18] JiS, QinY, ShiS, et al. ERK kinase phosphorylates and destabilizes the tumor suppressor FBW7 in pancreatic cancer. Cell Res. 2015;25(5):561-573.

[19] LiuH, LiuY, LiuW, ZhangW, XuJ. EZH2-mediated loss of miR-622 determines CXCR4 activation in hepatocellular carcinoma. Nat Commun. 2015;6:8494.

[20] LoveMI, HuberW, AndersS. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550.

[21] MayersJR, Torrence ME, DanaiLV, et al. Tissue of origin dictates branched-chain amino acid metabolism in mutant Kras-driven cancers. Science (New York, NY). 2016;353(6304):1161-1165.

[22] NapolitanoG, Ballabio A. TFEB at a glance. J Cell Sci. 2016;129(13):2475-2481.

[23] YangC, WangX. Lysosome biogenesis: regulation and functions. J Cell Biol. 2021;220(6):e202102001.

[24] RauluseviciuteI, Riudavets-Puig R, Blanc-MathieuR, et al. JASPAR 2024:20th anniversary of the open-access database of transcription factor binding profiles. Nucleic Acids Res. 2023;52:D174-D182.

[25] LinY, ShiQ, YangG, et al. A small-molecule drug inhibits autophagy gene expression through the central regulator TFEB. Proc Natl Acad Sci USA. 2023;120(7):e2213670120.

[26] LeeM-S, DennisC, NaqviI, et al. Ornithine aminotransferase supports polyamine synthesis in pancreatic cancer. Nature. 2023;616(7956):339-347.

[27] WhiteE. The role for autophagy in cancer. J Clin Invest. 2015;125(1):42-46.

[28] Roczniak-FergusonA, Petit CS, FroehlichF, et al. The transcription factor TFEB links mTORC1 signaling to transcriptional control of lysosome homeostasis. Sci Signal. 2012;5(228):ra42.

[29] DoronzoG, Astanina E, CoràD, et al. TFEB controls vascular development by regulating the proliferation of endothelial cells. EMBO J. 2019;38(3):e98250.

[30] ArianoC, Costanza F, AkmanM, et al. TFEB inhibition induces melanoma shut-down by blocking the cell cycle and rewiring metabolism. Cell Death Dis. 2023;14(5):314.

[31] SettembreC, De Cegli R, MansuetoG, et al. TFEB controls cellular lipid metabolism through a starvation-induced autoregulatory loop. Nat Cell Biol. 2013;15(6):647-658.

[32] WongC-O, LiR, MontellC, Venkatachalam K. Drosophila TRPML is required for TORC1 activation. Current Biology: CB. 2012;22(17):1616-1621.

[33] LiT, ZhangZ, KolwiczSC, et al. Defective branched-chain amino acid catabolism disrupts glucose metabolism and sensitizes the heart to ischemia-reperfusion injury. Cell Metab. 2017;25(2):374-385.

[34] Di MaltaC, Ballabio A. TFEB-mTORC1 feedback loop in metabolism and cancer. Cell Stress. 2017;1(1):7-10.

[35] Bozadjieva KramerN, Evers SS, ShinJH, et al. The role of elevated branched-chain amino acids in the effects of vertical sleeve gastrectomy to reduce weight and improve glucose regulation. Cell Rep. 2020;33(2):108239.

[36] QianL, ZhangF, YinM, LeiQ. Cancer metabolism and dietary interventions. Cancer Biol Med. 2021;19(2):163-174.

[37] KellyB, PearceEL. Amino assets: how amino acids support immunity. Cell Metab. 2020;32(2):154-175.

[38] VivianJ, RaoAA, NothaftFA, et al. Toil enables reproducible, open source, big biomedical data analyses[J]. Nat Biotech. 2017;35(4):314-316.

RIGHTS & PERMISSIONS

2024 The Author(s). Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.